

# EURO IMAT2020

---

Organized by:



## INTERNATIONAL MEETING UPDATE IN ANTITHROMBOTIC TREATMENT 20-21 FEBRUARY 2020

HOTEL CROWNE PLAZA BARCELONA - FIRA CENTER  
AVENIDA RIUS I TAULET, 1-3 BARCELONA



Sponsored by:



# EURO IMAT2020

## INTERNATIONAL MEETING UPDATE IN ANTITHROMBOTIC TREATMENT 20-21 FEBRUARY 2020

### THURSDAY, FEBRUARY 20

15:20 15:30	<b>Welcome</b>
15:30 16:30	<b>Round Table discussion: What is your preferred anticoagulant agent in STEMI patients?</b> <ul style="list-style-type: none"><li>• Unfractionated heparin</li><li>• Low-molecular weight heparin</li><li>• Bivalirudin</li></ul>
16:30 17:00	<b>Controversy: Pretreatment in NSTEMACS</b>
17:00 17:20	Coffee break
17:20 18:20	<b>Case-based session: Management of antithrombotic therapy in complex PCI scenarios</b>
18:20 19:00	<b>Special lecture: Pharmacological characteristics of parenteral antiplatelet agents</b>

### FRIDAY, FEBRUARY 21

08:30 09:00	<b>Special lecture: Research in new antithrombotic agents. What's in the pipeline?</b>
09:00 10:00	<b>Controversy: Dual vs Triple Antithrombotic therapy in AF patients undergoing PCI. What's best?</b> <ul style="list-style-type: none"><li>• I prefer dual therapy in most cases</li><li>• I prefer triple therapy in most cases</li></ul>
10:00 10:30	Coffee break
10:30 11:00	<b>Special lecture: Antithrombotic therapy in TAVR</b>
11:00 12:00	<b>Round Table discussion: Relevant questions about antithrombotic therapy in ischemic heart disease.</b> <ul style="list-style-type: none"><li>• How to stratify ischemic and bleeding risks in a given patient?</li><li>• When to shorten ant when to prolong DAPT?</li><li>• How to use cangrelor?</li></ul>
12:00 13:00	Lunch
13:00 14:00	<b>Case-based session: Management of antithrombotic therapy in complex clinical scenarios.</b>
14:00 14:40	<b>Round Table discussion: New strategies of antithrombotic therapy in ischemic heart disease.</b> <ul style="list-style-type: none"><li>• Chairmen</li><li>• De-escalation of P2Y<sub>12</sub> inhibitors</li><li>• Dual therapy with rivaroxaban</li><li>• Monotherapy with potent P2Y<sub>12</sub> inhibitors</li></ul>
14:40 14:45	<b>Closure</b>